Fig. 1
From: Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
Flow diagram of the study. ALK+ NSCLC, anaplastic lymphoma kinase-positive non-small cell lung cancer; US, United States; FDA, Food and Drug Administration
Fig. 1 | BMC Cancer